Tectonic Therapeutic, Inc. (NASDAQ:TECX) Receives Average Recommendation of "Moderate Buy" from Brokerages

Key Points

• Analyst consensus: Seven analysts rate Tectonic Therapeutic a "Moderate Buy" (1 sell, 5 buy, 1 strong buy) with an average 12‑month target of $81.50; recent notes include Truist cutting its target to $60 and Lifesci upgrading to strong‑buy while Weiss reissued a sell.
• Insider activity: CFO Daniel Lochner bought 6,000 shares at $21.61 (a 23.04% increase in his stake), while insider Peter McNamara sold 6,262 shares at $30.17; insiders have sold 19,561 shares in the past 90 days and own 9.20% of the stock.
• Institutional backing and stock metrics: Large institutional investors (Aberdeen, Baker Bros., Braidwell, Orbimed) have added sizable positions and institutions own 62.63% of the shares; market cap is ~$638.5M, shares recently opened at $34 with a 50‑day MA of $22.05 and the company remains unprofitable (negative EPS).

Tectonic Therapeutic, Inc. (NASDAQ:TECX - Get Free Report) has been given a consensus rating of "Moderate Buy" by the seven analysts that are currently covering the firm, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, five have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month target price among brokers that have updated their coverage on the stock in the last year is $81.50.

A number of brokerages have commented on TECX. Truist Financial decreased their price target on shares of Tectonic Therapeutic from $64.00 to $60.00 and set a "buy" rating for the company in a research note on Thursday, January 8th. Lifesci Capital upgraded shares of Tectonic Therapeutic to a "strong-buy" rating in a report on Thursday, February 5th. Finally, Weiss Ratings reissued a "sell (d-)" rating on shares of Tectonic Therapeutic in a research report on Thursday, January 22nd.

Insider Buying and Selling

In related news, CFO Daniel Lochner purchased 6,000 shares of the stock in a transaction that occurred on Tuesday, February 10th. The stock was acquired at an average cost of $21.61 per share, with a total value of $129,660.00. Following the transaction, the chief financial officer owned 32,044 shares of the company's stock, valued at $692,470.84. This represents a 23.04% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Peter Mcnamara sold 6,262 shares of Tectonic Therapeutic stock in a transaction on Friday, March 6th. The stock was sold at an average price of $30.17, for a total transaction of $188,924.54. Following the transaction, the insider directly owned 55,285 shares in the company, valued at $1,667,948.45. This represents a 10.17% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last 90 days, insiders sold 19,561 shares of company stock worth $566,551. 9.20% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Tectonic Therapeutic

A number of institutional investors have recently added to or reduced their stakes in TECX. Aberdeen Group plc grew its stake in Tectonic Therapeutic by 220.6% in the 4th quarter. Aberdeen Group plc now owns 1,141,824 shares of the company's stock valued at $23,818,000 after purchasing an additional 785,648 shares during the period. Braidwell LP grew its position in Tectonic Therapeutic by 25.9% during the fourth quarter. Braidwell LP now owns 927,524 shares of the company's stock valued at $19,348,000 after buying an additional 190,657 shares during the period. Baker BROS. Advisors LP raised its position in Tectonic Therapeutic by 803.4% in the fourth quarter. Baker BROS. Advisors LP now owns 903,400 shares of the company's stock worth $18,845,000 after acquiring an additional 803,400 shares during the period. 5AM Venture Management LLC boosted its stake in Tectonic Therapeutic by 18.6% in the fourth quarter. 5AM Venture Management LLC now owns 606,660 shares of the company's stock valued at $12,655,000 after acquiring an additional 95,000 shares during the last quarter. Finally, Orbimed Advisors LLC bought a new position in shares of Tectonic Therapeutic during the 4th quarter valued at approximately $11,986,000. 62.63% of the stock is owned by institutional investors.

Tectonic Therapeutic Price Performance

Shares of TECX opened at $34.00 on Tuesday. The stock has a 50-day moving average of $22.05 and a 200-day moving average of $19.80. The company has a market cap of $638.52 million, a PE ratio of -8.40 and a beta of 3.75. Tectonic Therapeutic has a one year low of $13.70 and a one year high of $36.03.

Tectonic Therapeutic (NASDAQ:TECX - Get Free Report) last announced its quarterly earnings results on Thursday, February 26th. The company reported ($1.03) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.11) by $0.08. Analysts expect that Tectonic Therapeutic will post -8.31 EPS for the current fiscal year.

Tectonic Therapeutic Company Profile

Tectonic Therapeutic, Inc engages in discovery and development of therapeutic proteins & antibodies. The company was founded by Timothy A. Springer and Andrew Kruse in 2019 and is headquartered in Watertown, MA.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.